MK-8527 for Healthy Subjects

Overseen By Study Coordinator

Age: 18 - 65

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Merck Sharp & Dohme LLC

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

Research Team

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Eligibility Criteria

This clinical trial is for healthy adults with a BMI between 18 to 32 kg/m2. Participants should be in good overall health without any significant medical conditions.

Inclusion Criteria

I am in good health overall.

My BMI is between 18 and 32.

Treatment Details

Interventions

• MK-8527 (Other)

Trial Overview [14C]MK-8527 is being tested to understand how it's absorbed, metabolized, and excreted by the body in healthy individuals. This study will track the movement of the drug through the body over time.

Participant Groups

Group I: [14C]MK-8527 Experimental Treatment 1 Intervention

Participants will receive a single oral dose of \[14C\]MK-8527 on Day 1

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University